

**Circular No. (31) 2021**

Date: 24<sup>th</sup> November 2021

**To: All Physicians**

**SUBJECT: PRISCRIBING OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES:  
VICTOZA, SAXENDA, OZEMPIC**

Dear All,


With reference to the above subject matter, it has been noticed lately that the GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES: VICTOZA, SAXENDA, OZEMPIC are being prescribed to regular patients for wight loss, where only **SAXENDA** has been approved for such use.

With immediate effect all **GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES: VICTOZA, and OZEMPIC** should be prescribed for the approved indication only as mentioned below and it will be monitored closely from the date of this circular.

Approved indication: for the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise: as monotherapy when metformin is considered inappropriate due to intolerance or contraindications or in addition to other medicinal products for the treatment of diabetes.

It is important to clarify that you will be holding full legal responsibility regarding failure to do so.

Your cooperation is highly appreciated.



**Dr Mariam Athbi Al-Jalahma**  
**Chief Executive Officer**